Spencer Feldman

Only about 0.01% of biologic drugs reach glioblastoma tumors, but convection-enhanced delivery bypasses the barrier to deliver therapy directly to the brain.

Dr. Jonathan W. Friedberg says long-term data show 42% of treated follicular lymphoma patients achieved functional cure with chemoimmunotherapy.

Resilience programs using mindfulness and cognitive behavioral strategies help cancer survivors manage their fear and stress, as well as adjust after treatment.

Common myths about cervical cancer and HPV may discourage screening. Experts say vaccination helps but does not replace regular testing.

FDA approvals, survival gains and equity research led February’s top gynecologic cancer stories, alongside a survivor Q&A on mental health.

February 2026 coverage highlighted combination EGFR therapy guidance, chemo-free treatment options, biomarker testing and survivorship lung health.

Four new and ongoing lung cancer trials are enrolling patients, offering options in first-line and previously treated NSCLC settings.

Overview of nodular sclerosis Hodgkin lymphoma, including diagnosis, staging, treatment options by stage and possible side effects.

Subcutaneous Rybrevant plus Keytruda led to a 56% response rate in recurrent or metastatic head and neck cancer in OrigAMI-4.

FDA approved Hernexeos for untreated HER2-mutant NSCLC after 76% of patients had tumor shrinkage in clinical trial data.

The OriGAMI-4 trial reveals subcutaneous Rybrevant's 45% response rate in metastatic head and neck cancer patients after immunotherapy and platinum.

FDA removal of an exclusion allows Yescarta use in primary CNS lymphoma, showing safety and strong efficacy in relapsed disease.

Thsi overview explains mesothelioma staging, diagnosis, side effects and treatment options from frontline through later lines to guide patient discussions.

FDA approves Calquence with Venclexta as a first-line option that improved progression-free survival compared with standard chemo in adults with CLL or SLL.

App-based self-acupressure improved fatigue and quality of life for women with ovarian cancer in a phase 3 trial, with benefits lasting to 24 weeks.

This device detects and characterizes lesions on low-dose CT scans, helping patients with cancer get faster, tailored care and avoid unnecessary procedures.

Study finds survival was similar during ovarian cancer trials, but gaps returned after, underscoring need for broader, more inclusive enrollment.

Patients with stage 4 lung cancer and EGFR mutations may benefit from combination therapies that improve disease control.

Black patients were underrepresented in ovarian cancer trials and had lower overall survival than White patients in a pooled analysis of 1,903 participants.

Overview of diagnosis, stage-based treatments, side effects and follow-up to help patients with cancer understand care choices and expectations.

A three-time survivor stresses second opinions, therapy and caregiver self-care to help patients navigate treatment, recovery and life after surgery.

Heather Quintana Suchan, a nonsmoker with stage 4 lung cancer, credits genomic testing and Rybrevant and urges others not to ignore mild symptoms.

Riozzi Bodine shares how her daughter’s diagnosis inspired the launch of a foundation offering cold caps, wigs and caregiver support.

A nurse practitioner explains how FDA approval of subcutaneous Rybrevant may reduce treatment burden and improve care for patients with EGFR-mutated lung cancer.

Showing up taking notes and learning the disease can help families feel empowered as new treatments expand hope and quality of life.

FDA OKs Keytruda with paclitaxel for PD-L1 positive, platinum-resistant ovarian, fallopian tube or peritoneal cancers, improving survival and delaying growth.

In CATNON, 12 cycles after radiation extended median survival past 12 years in IDH-mutant disease while concurrent dosing showed no benefit.

Drs. Miller, Orringer and Yang explain IDH testing, treatment options, quality of life and caregiver roles for patients with IDH-mutant glioma.

Hodgkin lymphoma is a cancer of the lymphatic system, which includes lymph nodes, the spleen and immune cells that help the body fight infection.

FDA expands access to CAR-T cell therapy for patients with relapsed or refractory PCNSL.